Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics Q2 loss $83.7 million; share sale program raised to $463 million

Negative Impact 4 of 5 earnings Written later

Relay Therapeutics reported a second quarter 2026 net loss of $83.7 million, or $0.41 per share, up from $70.4 million a year earlier, on revenue of $0.4 million. On August 6, 2026, the company also amended its at-the-market stock sale agreement with TD Cowen to raise the program from $250 million to $462,978,049, which may add new shares and dilute existing holders.

Key points

  • Q2 2026 net loss was $83.7 million, or $0.41 per share, versus a net loss of $70.4 million, or $0.41 per share, in Q2 2025.
  • Q2 2026 revenue was $0.4 million, down from $0.7 million; R&D expenses rose to $76.5 million from $63.9 million.
  • Cash, cash equivalents and investments were $910.9 million as of June 30, 2026, which the company says funds operations into 2029.
  • The at-the-market program now allows up to $462,978,049; about $162,978,049 has been sold, and a new prospectus supplement covers up to $212,978,049 more.

The filing

CompanyRelay Therapeutics, Inc. (RLAY)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:11 PM ET
Accession number0001193125-26-338013

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.